Form 4: PTC Therapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
PTC Therapeutics CEO Matthew B. Klein sold 3,361 shares of common stock on April 19, 2024, to cover tax obligations related to vesting RSUs.
Summary
- On April 19, 2024, Matthew B. Klein, CEO of PTC Therapeutics, sold 3,361 shares of common stock.
- The sale was executed at a price of $24.894 per share.
- The transaction was conducted to cover tax withholding obligations associated with the vesting of 6,500 Restricted Stock Units (RSUs) from a grant made on April 18, 2023.
- Following the transaction, Klein directly owns 225,807 shares of PTC Therapeutics common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transaction is a routine sale of shares to cover tax obligations, which is a common practice and doesn't necessarily reflect a positive or negative outlook on the company.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and are generally not indicative of a negative outlook on the company's future performance.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| 04/18/2023 | Date of grant of 26,000 RSUs |
| 04/19/2024 | Date of stock sale to cover tax obligations |
| 04/22/2024 | Date of signature of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.